An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic), Confirmed Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF), for Whom Standard Systemic Therapy Has Failed or Progressed, in Whom There Are no Satisfactory Treatment Alternatives and Who Are Not Eligible for Other Clinical Trials.

EAR688789-CH

Kidney cancer belongs to a heterogeneous group of tumors and is the most common oncourological disease; up to 80% of cases are clear cell carcinoma.

-1

Inclusion Criteria: * Histologically documented metastatic renal cell cancer or cell kidney cancer * Evidence of measurable disease. * Adequate renal function (serum creatinine level) * ECOG Status 0-1 * Patient must provide signed informed consent * Male or female, age \>/= 18 years Exclusion Criteria: * Current use or anticipated need for treatment with drugs that are known potent CYP3A4 inhibitors * Current use or anticipated need for treatment with drugs that are known as potent CYP3A4 or CYP1A2. * Active gastrointestinal bleeding. * Severe allergic reactions * Unwillingness or inability to comply with mandated pretreatment biopsy or therapeutic regimen

{'studyType': 'EXPANDED_ACCESS', 'expandedAccessTypes': {'individual': True}}

2023-07-12